C83.48 Immunoblastic (diffuse) non-Hodgkin's lymphoma, lymph nodes of multiple sites

Name of the Condition

• Immunoblastic (diffuse) non-Hodgkin's lymphoma, lymph nodes of multiple sites
• Also known as ICD-10 code C83.48

Summary

Immunoblastic (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of immunoblasts, a type of immature B-cell. It typically involves diffuse growth patterns in lymph nodes or other lymphoid tissues, with a tendency for rapid progression. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific subtype.

Causes

The exact cause of immunoblastic (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in B-cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or PET scans), and biopsy of affected lymph nodes. Laboratory tests, including blood work and bone marrow aspiration, may also be performed to assess disease extent and rule out other conditions. Pathological analysis of tissue samples confirms the diagnosis by identifying immunoblasts and characteristic cellular patterns.

Treatment Options

Treatment depends on disease stage, patient health, and subtype. Options may include chemotherapy, immunotherapy, targeted therapy, or radiation. Stem cell transplantation may be considered for advanced cases. Multidisciplinary care involving oncologists, hematologists, and other specialists is typical.

Prognosis and Follow-Up

Prognosis varies based on factors like age, overall health, and response to treatment. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or progression. Long-term surveillance helps manage potential late effects of therapy.

Complications

Potential complications include infection due to immunosuppression, organ dysfunction from tumor burden, treatment-related side effects (e.g., neuropathy, cardiotoxicity), and transformation to more aggressive lymphoma subtypes.

Lifestyle & Prevention

While prevention is not fully established, maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known carcinogens (e.g., tobacco) may support overall health. Managing chronic infections or immune conditions under medical guidance is advisable.

When to Seek Professional Help

Seek prompt medical evaluation for persistent swollen lymph nodes, unexplained weight loss, fever, or night sweats. Early consultation is critical for accurate diagnosis and timely intervention.

Tips for Medical Coders

Code C83.48 is specific to immunoblastic (diffuse) non-Hodgkin's lymphoma involving lymph nodes of multiple sites. Documentation should clearly specify the anatomical distribution and confirm the diagnosis via pathology. Ensure alignment with ICD-10-CM guidelines for site-specific lymphoma coding to avoid miscoding.